| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
The primary targets of Lancerin are not definitively established in the available literature. As a xanthone compound with antioxidative properties, Lancerin is believed to exert its effects through the scavenging of reactive oxygen species (ROS) and inhibition of lipid peroxidation. Xanthones are known to interact with various cellular targets involved in oxidative stress pathways, including enzymes such as xanthine oxidase, cyclooxygenases, and lipoxygenases. Lancerin may also modulate signaling pathways related to inflammation and cell survival through its antioxidant activity. However, specific receptor or enzyme targets have not been conclusively identified. The compound's mechanism of action is primarily attributed to its ability to neutralize free radicals and prevent oxidative damage to cellular membranes and biomolecules.
|
|---|---|
| ln Vitro |
Lancerin demonstrates significant in vitro antioxidative activity against lipid peroxidation. The compound effectively scavenges free radicals and inhibits the oxidative degradation of lipids, which is a key mechanism underlying its protective effects against oxidative stress-induced cellular damage. Lancerin's xanthone structure contributes to its antioxidant capacity through the presence of multiple hydroxyl groups that can donate hydrogen atoms to neutralize reactive oxygen species. The compound has been shown to exhibit anti-lipid peroxidation activity, suggesting its potential utility in preventing oxidative damage in biological systems. Lancerin's high purity (≥98%) ensures consistent activity in biochemical assays. The compound is soluble in DMSO and methanol, facilitating its use in various in vitro experimental systems.
|
| ln Vivo |
In vivo activity data for Lancerin are limited. As a natural product with antioxidative properties, Lancerin has the potential to exert protective effects against oxidative stress in living organisms. The compound's anti-lipid peroxidation activity observed in vitro suggests that it may offer benefits in animal models of oxidative stress-related conditions. However, comprehensive pharmacokinetic and pharmacodynamic studies in animal models have not been extensively reported. The compound is extracted from the root bark of Cudrania cochinchinensis and has been studied primarily for its chemical properties and in vitro biological activities. Further research is needed to establish its in vivo efficacy, safety profile, and therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Lancerin typically involves measuring its antioxidant activity, particularly its ability to inhibit lipid peroxidation. The assay protocol commonly uses a lipid peroxidation system such as linoleic acid or rat liver microsomes, with peroxidation induced by free radical generators like Fe2+/ascorbate or AAPH. Lancerin is added at varying concentrations to the reaction mixture, and the extent of lipid peroxidation is measured by quantifying malondialdehyde (MDA) formation using the thiobarbituric acid reactive substances (TBARS) assay. The compound's free radical scavenging activity can be assessed using DPPH or ABTS radical scavenging assays. Incubations are typically performed at 37degC for 30-60 minutes, and absorbance is measured spectrophotometrically. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
The in vitro cell-based assay for Lancerin involves culturing relevant cell lines and treating them with varying concentrations of the compound to assess its cytoprotective effects against oxidative stress. Cells such as fibroblasts, hepatocytes, or neuronal cells are typically seeded in multi-well plates and pre-incubated with Lancerin (1-100 uM) for 1-24 hours. Oxidative stress is then induced using hydrogen peroxide, tert-butyl hydroperoxide, or other oxidizing agents. Cell viability is assessed using MTT, CCK-8, or LDH release assays to determine the compound's protective effects. Additionally, intracellular ROS levels can be measured using fluorescent probes such as DCFH-DA, and lipid peroxidation can be assessed using MDA or 4-HNE assays. Lancerin is soluble in DMSO and methanol but insoluble in water.
|
| Animal Protocol |
In vivo animal studies for Lancerin have not been extensively documented in the literature. Based on the compound's antioxidative properties and anti-lipid peroxidation activity, potential animal studies would typically involve administration of Lancerin via oral, intraperitoneal, or intravenous routes in rodent models of oxidative stress-related conditions such as hepatic injury, neurodegenerative diseases, or cardiovascular disorders. Dosing would be determined based on preliminary pharmacokinetic data and solubility profiles. Common endpoints in such studies would include evaluation of oxidative stress markers (MDA, SOD, CAT, GSH), assessment of tissue damage, and monitoring of general toxicity parameters. However, comprehensive in vivo efficacy and toxicity studies have not been widely reported for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Lancerin have not been fully characterized in the literature. The compound has a molecular weight of 406.34 g/mol and a molecular formula of C1₉H1₈O10. Lancerin is soluble in DMSO and methanol but insoluble in water. The compound has a density of 1.761 g/cm3 at 20degC. For storage, Lancerin powder can be kept at -20degC for 3 years, and in solution at -80degC for 1 year. The compound should be stored desiccated and kept tightly sealed. When stored as directed, the product remains stable for up to 24 months at 2-8degC. The compound has a predicted LogP value indicative of moderate lipophilicity.
|
| Toxicity/Toxicokinetics |
Toxicity data for Lancerin are limited, as the compound is a research-use natural product and has not undergone extensive toxicological characterization. Standard safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment such as gloves and lab coats to prevent skin contact and inhalation of dust. The compound should be handled in a well-ventilated area. In case of accidental exposure, rinse affected areas with plenty of water and seek medical attention if irritation persists. Proper waste disposal procedures should be observed in accordance with local regulations. As with all research chemicals, exposure should be minimized and the compound should be stored securely away from incompatible materials.
|
| References | |
| Additional Infomation |
Lancerin is a C-glycoside compound with the structure 9H-xanthone-9-one, substituted with hydroxyl groups at positions 1, 3, and 7, and a 1,5-dehydro-D-glucol moiety at position 1. It is a plant metabolite belonging to the xanthone class of compounds, and is also a C-glycoside and polyphenol. Lancerin has been reported to exist in Polygala tenuifolia, Schultesia lisianthoides, and other organisms with relevant data.
Lancerin (CAS#: 81991-99-3) is a naturally occurring xanthone with the molecular formula C1₉H1₈O10 and a molecular weight of 406.34. Also known as 4-beta-D-glucosyl-1,3,7-trihydroxyxanthone, Lancerin is extracted from the root bark of Cudrania cochinchinensis and exhibits antioxidative activity against lipid peroxidation. The compound has a purity of ≥98% and is soluble in DMSO and methanol but insoluble in water. Lancerin has gained attention for its potential therapeutic applications due to its antioxidant properties. The compound is intended for research purposes only and is not approved for human therapeutic use. No clinical trials or regulatory approvals have been reported for Lancerin. The compound is suitable for quantitative analysis, quality control, and biochemical research. |
| Molecular Formula |
C19H18O10
|
|---|---|
| Molecular Weight |
406.34022
|
| Exact Mass |
406.089
|
| CAS # |
81991-99-3
|
| PubChem CID |
5281645
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
770.2±60.0 °C at 760 mmHg
|
| Melting Point |
225-227 °C
|
| Flash Point |
279.3±26.4 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.761
|
| LogP |
0.55
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
29
|
| Complexity |
616
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC2=C(C=C1O)C(=O)C3=C(O2)C(=C(C=C3O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
JUZGXATTXYZBGK-HBVDJMOISA-N
|
| InChi Code |
InChI=1S/C19H18O10/c20-5-11-15(25)16(26)17(27)19(29-11)13-9(23)4-8(22)12-14(24)7-3-6(21)1-2-10(7)28-18(12)13/h1-4,11,15-17,19-23,25-27H,5H2/t11-,15-,16+,17-,19+/m1/s1
|
| Chemical Name |
1,3,7-trihydroxy-4-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~307.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4610 mL | 12.3050 mL | 24.6099 mL | |
| 5 mM | 0.4922 mL | 2.4610 mL | 4.9220 mL | |
| 10 mM | 0.2461 mL | 1.2305 mL | 2.4610 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
